Efficacy of immune-oncology combinations versus sunitinib in patients with bone metastases from renal cell carcinoma: A systematic review and meta-analysis of phase III trials with long-term follow-up
Bone metastases are common in kidney cancer and carry a poor prognosis, so the choice of systemic therapy shapes survival in patients an orthopaedic surgeon may be asked to stabilize or fix.
Rigour42/100
Clinical48/100
Impact†53/100
Source band: Limited